Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Return on Sales (2016 - 2025)

Editas Medicine (EDIT) has disclosed Return on Sales for 11 consecutive years, with 3.33% as the latest value for Q3 2025.

  • Quarterly Return on Sales rose 101529.0% to 3.33% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 4.26% through Sep 2025, down 85.0% year-over-year, with the annual reading at 7.34% for FY2024, 540.0% down from the prior year.
  • Return on Sales for Q3 2025 was 3.33% at Editas Medicine, up from 14.39% in the prior quarter.
  • The five-year high for Return on Sales was 0.31% in Q4 2023, with the low at 1326.83% in Q3 2022.
  • Average Return on Sales over 5 years is 146.62%, with a median of 8.73% recorded in 2021.
  • The sharpest move saw Return on Sales tumbled -131958bps in 2022, then soared 131840bps in 2023.
  • Over 5 years, Return on Sales stood at 4.38% in 2021, then crashed by -112bps to 9.29% in 2022, then surged by 97bps to 0.31% in 2023, then tumbled by -372bps to 1.48% in 2024, then crashed by -124bps to 3.33% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 3.33%, 14.39%, and 16.24% for Q3 2025, Q2 2025, and Q1 2025 respectively.